

International Transfer & Consolidation of Production Sites



COMPANY OVERVIEW

Global medicinal company, headquarters in Switzerland



PROJECT DESCRIPTION

Coordination of transfer and validation activities for production site transfer of production processes, equipment, test methods, IT infrastructure, applications and know-how ▪ Harmonization and definition of business processes



CHALLENGES & OPPORTUNITIES

International transfer and consolidation of two production sites (Austria, Switzerland) to a new location (Switzerland) and a new quality system ▪ Heterogeneous product portfolio and different levels of process and product documentation across as well as within sites ▪ Strict timelines due to fixed site closure

RESULTS & CUSTOMER BENEFITS

Successful transfer of production equipment, processes and knowledge within timelines ▪
Harmonized and improved documentation standards ▪
Successful FDA site-inspection

Research Center Move & Application Portfolio Optimization



COMPANY OVERVIEW

Global pharmaceutical company, headquarters in Switzerland



PROJECT DESCRIPTION

Coordination of the transfer of all research applications and corresponding knowledge from one site to another ■ Coordination of 37 projects to transfer software from the shutdown site



CHALLENGES & OPPORTUNITIES

Research center move ■ Knowledge retention & transfer

RESULTS & CUSTOMER BENEFITS

Successful transfer of all relevant applications including adaption to target site ■ Cost savings by decommissioning of outdated applications ■ Knowledge transfer and user trainings at target site ■ Securing all relevant research data ■ Reduction of overall operational footprint

Global Unbundling Program after Divestment



COMPANY OVERVIEW

Global pharmaceutical company, headquarters in Switzerland



PROJECT DESCRIPTION

Managing all informatics-related activities of the divestment processes in a flexible agile two-step approach: First, creating “stand-alone” informatics and second, integration into buyer’s IS architecture



CHALLENGES & OPPORTUNITIES

Divestment of four drug product manufacturing sites due to restructuring of the manufacturing network for small molecule products ▪ Unbundling of IT infrastructure for planned divestment to unknowing buyer while minimizing job reductions

RESULTS & CUSTOMER BENEFITS

Reduced complexity in divestment process while providing stand-alone IS ▪ Smooth unbundling without impacting production IS of retained organization ▪ Delivered the project under budget for both, unbundling and integration activities